AMNEAL PHARMACEUTICALS, INC. $AMRX Holdings Lifted by Raymond James Financial Inc.

Key Points

• Raymond James Financial Inc. increased its stake in AMNEAL PHARMACEUTICALS by 60.4% during the 1st quarter, owning around 596,502 shares valued at approximately $5 million.
• Other institutional investors, including Vanguard Group and Invesco, have also increased their holdings in AMNEAL PHARMACEUTICALS, with hedge funds owning 31.82% of the stock.
• AMNEAL recently reported $0.23 EPS for the last quarter, surpassing analysts' expectations, and set a FY 2025 guidance of 0.700-0.750 EPS.

Raymond James Financial Inc. lifted its holdings in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 60.4% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 596,502 shares of the company's stock after acquiring an additional 224,506 shares during the quarter. Raymond James Financial Inc. owned 0.19% of AMNEAL PHARMACEUTICALS worth $4,999,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. GAMMA Investing LLC raised its stake in AMNEAL PHARMACEUTICALS by 5,975.0% during the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after acquiring an additional 3,107 shares during the period. Headlands Technologies LLC purchased a new stake in AMNEAL PHARMACEUTICALS in the first quarter valued at approximately $31,000. Amalgamated Bank boosted its position in AMNEAL PHARMACEUTICALS by 33.0% in the 1st quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after purchasing an additional 1,367 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in AMNEAL PHARMACEUTICALS in the 4th quarter valued at $52,000. Finally, Xponance Inc. increased its position in shares of AMNEAL PHARMACEUTICALS by 16.1% during the 1st quarter. Xponance Inc. now owns 13,183 shares of the company's stock worth $110,000 after purchasing an additional 1,828 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

AMNEAL PHARMACEUTICALS Trading Down 0.7%

Shares of NASDAQ:AMRX traded down $0.07 during trading on Wednesday, reaching $9.82. 1,729,077 shares of the stock were exchanged, compared to its average volume of 1,467,692. The stock has a 50-day moving average price of $8.77 and a 200-day moving average price of $8.17. The firm has a market cap of $3.08 billion, a PE ratio of 982.98 and a beta of 1.19. AMNEAL PHARMACEUTICALS, INC. has a 12 month low of $6.68 and a 12 month high of $9.97.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. On average, sell-side analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Wall Street Zen lowered AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group started coverage on AMNEAL PHARMACEUTICALS in a report on Friday, June 6th. They set a "buy" rating and a $12.00 target price on the stock. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, AMNEAL PHARMACEUTICALS presently has an average rating of "Buy" and a consensus price target of $11.60.

Insider Buying and Selling at AMNEAL PHARMACEUTICALS

In other AMNEAL PHARMACEUTICALS news, Director John Kiely sold 32,000 shares of AMNEAL PHARMACEUTICALS stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total transaction of $295,360.00. Following the completion of the sale, the director directly owned 225,433 shares in the company, valued at approximately $2,080,746.59. The trade was a 12.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Jason B. Daly sold 22,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $9.05, for a total transaction of $199,100.00. Following the completion of the sale, the executive vice president directly owned 10,606 shares of the company's stock, valued at $95,984.30. This represents a 67.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 609,206 shares of company stock valued at $5,700,625 in the last ninety days. Corporate insiders own 26.56% of the company's stock.

About AMNEAL PHARMACEUTICALS

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.